8月8日，Glaukos Corp盘中上涨5.46%，报180.25美元/股，成交额1.05亿美元。
消息面上，公司此前发布的Q2财报大幅超出市场预期：调整后每股亏损收窄至0.14美元，优于市场预期的亏损0.22美元；营收达1.856亿美元，较预期的1.509亿美元高出约23%。同时，公司将全年营收指引上调至6.8亿至7亿美元，远高于市场此前预估的6.3亿美元。
财报发布后，多家机构密集上调目标价：Needham将目标价从150美元大幅调升至201美元，HC Wainwright上调至195美元，均维持买入评级。此外，公司Preserflo微型引流器510(k)关键性研究已完成患者入组，为后续产品获批奠定基础，进一步强化了市场对公司成长前景的乐观预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.